◎ Sugi Atlas

Atlas / Drug / Aprepitant

Aprepitant

drug
On this page

Also known as AponvieCinvantiEmendL-754,030MK-0869MK-869NSC-748825Ono-7436APREPITANT (MK-0869)L-754030APREPITANT`Aprepitant

Summary

Aprepitant (CHEMBL1471) is an approved small-molecule antidepressant (ATC A04AD12) targeting TACR1; indicated across 24 conditions including neoplasm and plasma cell myeloma.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A04AD12
  • Targets: 1 (TACR1)
  • Indications: 24 conditions
  • Clinical trials: 156
  • Chemistry: 534.4 Da · C23H21F7N4O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1471
NameAprepitant
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID135413536
ChEBICHEBI:499361
ATCA04AD12
Molecular formulaC23H21F7N4O3
Molecular weight534.4
InChIKeyATALOFNDEOCMKK-OITMNORJSA-N

SMILES: C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F

IUPAC name: 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one

ChEBI definition: A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

Pharmacological roles (ChEBI): antidepressant, antiemetic, peripheral nervous system drug, neurokinin-1 receptor antagonist, substance P receptor antagonist.

Also known as: Aponvie, Aprepitant, Cinvanti, Emend, L-754,030, MK-0869, MK-869, NSC-748825, Ono-7436, APREPITANT, APREPITANT (MK-0869), EMEND

Patent coverage: 385 distinct patent families (901 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 667 (74%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TACR1NK1 receptorAntagonist10.050.7%P25103

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: G-protein coupled receptor 35, Substance-P receptor, Glucocorticoid receptor, Delta-type opioid receptor, Substance-P receptor, Androgen receptor, G-protein coupled receptor 183, fMet-Leu-Phe receptor, Cytochrome P450 3A4, G-protein coupled receptor 65.

Bioactivity

ChEMBL activities: 26 potent at pChembl ≥ 5 of 30 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
TACR110.1Ki0.08nMCHEMBL_ACT_13889610
TACR110.07Kd0.09nMCHEMBL_ACT_29171060
TACR110.05IC500.09nMCHEMBL_ACT_1254199
TACR110.05IC500.09nMCHEMBL_ACT_13508464
Q5DUB110.05IC500.09nMCHEMBL_ACT_15658679
TACR110.05IC500.09nMCHEMBL_ACT_1760876
TACR110.05IC500.09nMCHEMBL_ACT_1763723
TACR110.05IC500.09nMCHEMBL_ACT_178679
TACR110.05IC500.09nMCHEMBL_ACT_1982366
TACR110.05IC500.09nMCHEMBL_ACT_25041355
TACR110.05IC500.09nMCHEMBL_ACT_25050140
TACR110.05IC500.09nMCHEMBL_ACT_2556618
TACR110.05IC500.09nMCHEMBL_ACT_300351
TACR110IC500.1nMCHEMBL_ACT_1178717
TACR19.1Ki0.8nMCHEMBL_ACT_12183549
TACR18.85IC501.41nMCHEMBL_ACT_24387273
TACR18.52Ki3nMCHEMBL_ACT_12183560
TACR18.08Kd8.32nMCHEMBL_ACT_12183596
CYP3A47.7IC5020nMCHEMBL_ACT_26785337
CYP3A47.7IC5020nMCHEMBL_ACT_26965303
CYP3A47.7IC5020nMCHEMBL_ACT_27680486
CYP3A47.34IC5046nMCHEMBL_ACT_1982446
TACR36.34Ki454.1nMCHEMBL_ACT_12183538
GPR655.73IC501874nMCHEMBL_ACT_25751405
GPR1835.35IC504513nMCHEMBL_ACT_25751403
GPR355.21IC506239nMCHEMBL_ACT_25751404

Target pathways

Aggregated over 1 target gene(s): TACR1.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Tachykinin receptors bind tachykinins1TACR1
G alpha (q) signalling events1TACR1
Cargo recognition for clathrin-mediated endocytosis1TACR1
Clathrin-mediated endocytosis1TACR1

Dominant GO biological processes

GO termTargets
aggressive behavior1
positive regulation of leukocyte migration1
angiotensin-mediated drinking behavior1
inflammatory response1
adenylate cyclase-activating G protein-coupled receptor signaling pathway1
phospholipase C-activating G protein-coupled receptor signaling pathway1
positive regulation of cytosolic calcium ion concentration1
phospholipase C-activating tachykinin receptor signaling pathway1
tachykinin receptor signaling pathway1
long-term memory1
associative learning1
detection of abiotic stimulus1
response to ozone1
positive regulation of epithelial cell migration1
response to auditory stimulus1

Indications & clinical

Indications

24 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070MONDO:0004992
plasma cell myeloma3MONDO:0009693EFO:0001378
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
germ cell tumor3MONDO:0005040EFO:0000514
major depressive disorder3MONDO:0002009MONDO:0002009
hepatocellular carcinoma3MONDO:0007256EFO:0000182
acute myeloid leukemia2MONDO:0018874EFO:0000222
gastroparesis2MONDO:0006769EFO:1000948
cocaine dependence2MONDO:0005186EFO:0002610
cannabis dependence2MONDO:0005689EFO:0007191
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
alcohol abuse2MONDO:0002046MONDO:0007079
HIV infectious disease1MONDO:0005109EFO:0000764
opiate dependence1MONDO:0005530EFO:0005611
heroin dependence1MONDO:0005367EFO:0004240
glioblastoma1MONDO:0018177EFO:0000519

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 156.

Phase distribution

PhaseTrials
PHASE344
PHASE232
Not specified31
PHASE429
PHASE116
PHASE1/PHASE22
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05841849PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT07371728PHASE4NOT_YET_RECRUITINGEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery
NCT00415103PHASE4COMPLETEDAMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
NCT00429754PHASE4WITHDRAWNPharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)
NCT00588835PHASE4TERMINATEDPharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
NCT00734929PHASE4COMPLETEDAprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
NCT00738621PHASE4COMPLETEDCombination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
NCT00781768PHASE4COMPLETEDOdansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea
NCT00888329PHASE4TERMINATEDAprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
NCT00977223PHASE4COMPLETEDEffects of Substance P Antagonists on Adrenal Secretion
NCT01298193PHASE4COMPLETEDIncidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
NCT01432015PHASE4COMPLETEDFosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01474915PHASE4COMPLETEDAprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
NCT01625455PHASE4TERMINATEDEffect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
NCT01636947PHASE4COMPLETEDA Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
NCT01897337PHASE4COMPLETEDThe Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
NCT01913990PHASE4UNKNOWNPrevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
NCT02021851PHASE4COMPLETEDPrevention of Nausea and Vomiting in Patients After Surgery
NCT02347878PHASE4UNKNOWNSelf-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
NCT02357693PHASE4COMPLETEDNeurokinin Receptor Antagonist Associated to Ondansetron in PONV
NCT02431286PHASE4UNKNOWNPalonosetron Associated to Aprepitant in Prophylaxis of PONV
NCT02532634PHASE4COMPLETEDRamosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
NCT02576327PHASE4UNKNOWNA Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
NCT04013386PHASE4COMPLETEDEffects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting
NCT04649229PHASE4COMPLETEDMechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
NCT05189756PHASE4TERMINATEDDual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.
NCT05632224PHASE4UNKNOWNPostoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery
NCT05772676PHASE4UNKNOWNThe Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
NCT06697782PHASE4COMPLETEDAprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
NCT06543966PHASE3NOT_YET_RECRUITINGEfficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
NCT07248280PHASE3RECRUITINGAdding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
NCT00034944PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
NCT00034983PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
NCT00035009PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
NCT00035048PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035282PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
NCT00035295PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
NCT00042029PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
NCT00048594PHASE3COMPLETEDLong Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
NCT00048607PHASE3COMPLETEDTreatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

44 molecules share ≥1 primary target. Top 44 by shared-target count:

MoleculeSourceStatusShared targets
ACLIDINIUM BROMIDEChEMBL + PubChemPhase 4 (approved)TACR1
FIDAXOMICINChEMBL + PubChemPhase 4 (approved)TACR1
ROLAPITANTChEMBL + PubChemPhase 4 (approved)TACR1
AMOXAPINEChEMBLPhase 4 (approved)TACR1
ARIPIPRAZOLEChEMBLPhase 4 (approved)TACR1
ASTEMIZOLEChEMBLPhase 4 (approved)TACR1
BOSUTINIBChEMBLPhase 4 (approved)TACR1
CARVEDILOLChEMBLPhase 4 (approved)TACR1
CLOTRIMAZOLEChEMBLPhase 4 (approved)TACR1
CYCLOSPORINEChEMBLPhase 4 (approved)TACR1
DEXTROMETHORPHANChEMBLPhase 4 (approved)TACR1
DOXAZOSINChEMBLPhase 4 (approved)TACR1
ECONAZOLEChEMBLPhase 4 (approved)TACR1
HALOPERIDOLChEMBLPhase 4 (approved)TACR1
ITRACONAZOLEChEMBLPhase 4 (approved)TACR1
LANSOPRAZOLEChEMBLPhase 4 (approved)TACR1
MICONAZOLEChEMBLPhase 4 (approved)TACR1
NEFAZODONEChEMBLPhase 4 (approved)TACR1
NETUPITANTChEMBLPhase 4 (approved)TACR1
NILOTINIBChEMBLPhase 4 (approved)TACR1
PAROXETINEChEMBLPhase 4 (approved)TACR1
RITONAVIRChEMBLPhase 4 (approved)TACR1
TAMOXIFENChEMBLPhase 4 (approved)TACR1
TERFENADINEChEMBLPhase 4 (approved)TACR1
THIOTHIXENEChEMBLPhase 4 (approved)TACR1
TRAZODONEChEMBLPhase 4 (approved)TACR1
CASOPITANTChEMBLPhase 3TACR1
SAREDUTANTChEMBLPhase 3TACR1
SERLOPITANTChEMBLPhase 3TACR1
BEFETUPITANTChEMBLPhase 2TACR1
DAPITANTChEMBLPhase 2TACR1
DNK333ChEMBLPhase 2TACR1
LANEPITANTChEMBLPhase 2TACR1
ORVEPITANTChEMBLPhase 2TACR1
OSANETANTChEMBLPhase 2TACR1
SPERGUALINChEMBLPhase 2TACR1
TALNETANTChEMBLPhase 2TACR1
TELMAPITANTChEMBLPhase 2TACR1
VESTIPITANTChEMBLPhase 2TACR1
VOFOPITANTChEMBLPhase 2TACR1
AlogliptinPubChemApprovedTACR1
BelzutifanPubChemApprovedTACR1
PropoxyphenePubChemApprovedTACR1
Tiotropium Bromide MonohydratePubChemApprovedTACR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot